VivoSeq
Nephrology

Nephrotic Syndrome

57

Pipeline Programs↗

22

Active Trials↗

30

Companies Involved↗

Nephrotic Syndrome is a moderately active landscape with 57 programs across 30 companies. The most active players are Astellas, Amgen, Aldeyra Therapeutics, Inc.. 17 therapies are approved with 15 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

30/100

Mech. Concentration

14/100

Completion Rate

68/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Astellas logo

Astellas

1 program

Phase 1Amgen logo

Amgen

1 program

Phase 2A

Aldeyra Therapeutics, Inc.

1 program

Phase 2Regeneron logo

Regeneron

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2I

Iovance Biotherapeutics, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical9

Montelukast

Organon and Co

Dexamethasone Sodium Phosphate

Quince Therapeutics S.p.A.

Tacrolimus

Veloxis Pharmaceuticals

Edoxaban

Daiichi Sankyo

Acthar

Mallinckrodt

Phase 12

Pravastatin

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Azithromycin and Steroids

University of Child Health Sciences and Children's Hospital, Lahore

Phase 214

Alirocumab

Regeneron

Dupilumab

Azienda U.S.L. 1 di Massa e Carrara

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Daratumumab

Johnson & Johnson

Ofatumumab

Novartis

Phase 315

Furosemide

Validus Pharmaceuticals

Telitacicept

Vor Biopharma

Mycophenolic Acid

Novartis

Cyclophosphamide

Baxter Healthcare Corporation

Rituximab

Roche

Approved17

Hydrochlorothiazide

AbbVie

Cyclosporine

Novartis

Cholestyramine

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Chlorthalidone

Alnylam Pharmaceuticals

Dapagliflozin

AstraZeneca

Analysis

Modality Breakdown

82%

Small molecule

59 of 72 classified programs — the dominant modality here.

18%ALL OTHERSMonoclonal antibody811%Protein / enzyme57%

Small molecule leads; the ring shows all 72 classified programs, each share of the total. Modality classified for 97% of 75 pipeline programs.

Analysis

Trial Status

74

clinical trials

Completed28 · 38%
Recruiting14 · 19%
Unknown status11 · 15%
Not yet recruiting7 · 9%
Terminated7 · 9%
Withdrawn4 · 5%
Other3 · 4%

Clinical Trials

Trial Activity

74 trials

Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome
Recruiting·—·Phase 2·NCT05843968·46 enrolled
Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome
Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 3·NCT06125405·20 enrolled
The Efficacy and Safety of Prednisone Combined With Huaiqihuang Granule for Primary Nephrotic Syndrome in Children
Recruiting·—·Phase 4·NCT05772871·402 enrolled
Dupilumab Therapy in Nephrotic Syndrome in Children
Recruiting·NNational University Hospital, Singapore·Phase 2·NCT07091175·66 enrolled
Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2/3·NCT05786768·88 enrolled
Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized，Open-label Clinical Trial.
Recruiting·—·Phase 3·NCT06079788·140 enrolled
The Role of Vitamin K2 in Preventing Glucocorticoid-Induced Bone Loss in Children With Nephrotic Syndrome
Recruiting·—·N/A·NCT07206537·60 enrolled
A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence
Recruiting·—·Phase 2·NCT07087314·30 enrolled
REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)
Recruiting·TThe Hospital for Sick Children·Phase 3·NCT06635720·50 enrolled
Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial
Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 3·NCT05734794·80 enrolled
Ketoanalogues for Muscle Mass Loss in Nephrotic Syndrome
Recruiting·MMilitary Institute od Medicine National Research Institute·Phase 3·NCT05716880·150 enrolled
Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children
Recruiting·TThe First Affiliated Hospital of Xiamen University·N/A·NCT06530004·50 enrolled
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00977977·30 enrolled
From Immune System Damage to Podocyte Cell Damage: Prospective Database and Biological Collection of Patients (Children and Adults) With Minimal Glomerular Injury Nephrotic Syndrome (MGLS) and Primary Segmental and Focal Hyalinosis (HSFP)
Recruiting·CCentre Hospitalier Universitaire de Nice·N/A·NCT04174066·144 enrolled
SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome
Active, not recruiting·MMansoura University·Phase 2/3·NCT07214818·75 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)